GeneMe secures a €5.2M round of seed funding led by Robin Tombs.

GeneMe, a Gdansk, Poland-based biotechnology company, announced that it completed a funding round of €5.2M ($6.3M).

The money was raised from investors led by Robin Tombs, Co-Founder of Yoti and previously of Gamesys, and other angel investors whose name was not disclosed.

The proceeds will be used for advancement of the platform and further refine its development of molecular NAAT COVID-19 tests: FRANKD, SAVD, and ICED and to consolidate emergency triage services by acquiring a minority stake in the medical-box startup Medicalls.

GeneMe, founded in 2018 by CEO Dawid Nidzworski, produces services related to polymorphisms analysis and broadly defined genetic tests. A spin-off from The Institute of Biotechnology and Molecular Medicine (IBMM), the company has developed and patented a universal protein (polymerase) for RT-LAMP testing, which allows the production of accurate, rapid, molecular genetic COVID tests. The fusion of this patented DNA polymerase with NeqSSB protein allows GeneMe to produce enzymes that refine the testing process, enabling analysis to be specific and scalable for mass use.